Earnings summaries and quarterly performance for Rapport Therapeutics.
Executive leadership at Rapport Therapeutics.
Board of directors at Rapport Therapeutics.
Research analysts covering Rapport Therapeutics.
Recent press releases and 8-K filings for RAPP.
Rapport Therapeutics Presents Positive RAP-219 Phase 2 Data and Pipeline Expansion
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics reported a strong financial position with approximately $513 million on its balance sheet as of September 30, 2025, providing a cash runway into the second half of 2029.
- The company released robust Phase 2 data in focal onset seizures for its lead program, RAP-219, in September 2025, demonstrating a 77.8% median reduction in clinical seizures and a 24% seizure freedom rate, and is accelerating the program into pivotal studies starting in Q2 2026.
- RAP-219 is also being developed for primary generalized tonic-clonic seizures and bipolar mania, with data for bipolar mania expected in H1 2027, and the company is developing a long-acting injectable formulation with initial human PK data anticipated in 2027. The total market opportunity across these indications is estimated at over $62 billion.
- Rapport nominated its first development candidate, the Alpha-6 beta-4 program, for chronic pain and migraine, which is entering IND-enabling studies with an update on clinic entry timing in 2026, and the company anticipates several data readouts and program advancements throughout 2026 and 2027.
Jan 14, 2026, 7:15 PM
Rapport Therapeutics Provides Update on RAP-219 Clinical Progress and Financial Position at J.P. Morgan Healthcare Conference
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics reported a strong financial position with $513 million on its balance sheet as of September 30, 2025, providing a cash runway into the second half of 2029.
- The company released robust Phase 2 data for its lead program, RAP-219, in focal onset seizures (FOS) in September 2025, demonstrating a median 77.8% reduction in clinical seizures and 24% seizure freedom. This positive outcome has led to accelerated progression into pivotal studies starting in Q2 2026.
- RAP-219's development pipeline is expanding to include primary generalized tonic-clonic seizures (PGTCS) and bipolar mania, with data for bipolar mania expected in the first half of 2027. A long-acting injectable formulation of RAP-219 is also in development, with first human PK data anticipated in 2027.
- From its discovery platform, Rapport Therapeutics nominated Alpha-6 beta-4 as its first development candidate for chronic pain and migraine, which is now entering IND-enabling studies.
Jan 14, 2026, 7:15 PM
Rapport Therapeutics Presents Positive RAP-219 Phase 2 Data and Pipeline Updates at J.P. Morgan Healthcare Conference
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics reported a strong financial position with $513 million on the balance sheet as of September 30, 2025, providing a cash runway into the second half of 2029.
- The company released robust Phase 2 data in focal onset seizures (FOS) for its lead program, RAP-219, in September 2025, demonstrating a median 77.8% reduction in clinical seizures and 24% seizure freedom. This positive data has led to the acceleration of pivotal studies for RAP-219 in FOS, which are set to begin in Q2 2026.
- Rapport is expanding the development of RAP-219 into primary generalized tonic-clonic seizures (PGTCS), with trial initiation expected in 2027, and a proof of concept study for bipolar mania, with data anticipated in H1 2027. Additionally, a long-acting injectable (LAI) formulation for RAP-219 is under development, with first human PK data expected in 2027.
- From its discovery platform, Rapport has nominated a development candidate for the Alpha-6 beta-4 program, targeting chronic pain and migraine, which is now entering IND-enabling studies.
Jan 14, 2026, 7:15 PM
Rapport Therapeutics Announces Accelerated RAP-219 Phase 3 Initiation and Epilepsy Portfolio Expansion
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics announced the accelerated initiation of its RAP-219 Phase 3 program for Focal Onset Seizures (FOS) to the second quarter of 2026, updated from its previous guidance of Q3 2026.
- The company is expanding its epilepsy portfolio with a new program in Primary Generalized Tonic-Clonic Seizures (PGTCS), with a Phase 3 trial planned for the first half of 2027.
- As of September 30, 2025, Rapport Therapeutics reported $513.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029.
- The FDA lifted the clinical hold on the Phase 2 diabetic peripheral neuropathic pain (DPNP) trial for RAP-219, but the company will defer investment in this program to prioritize its α6β4 program in chronic pain and migraine.
Jan 7, 2026, 12:30 PM
Rapport Therapeutics Announces Positive Phase 2 Results for RAP-219 and Outlines Development Milestones
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics recently released positive Phase 2 proof of concept results for its lead program, RAP-219, in focal onset seizures, demonstrating over 70% overall seizure reduction and 24% seizure freedom over an eight-week period, with a best-in-class tolerability profile.
- The company is scheduled to meet with the FDA in Q4 for an end-of-phase two meeting and plans to initiate pivotal studies in 2026 for RAP-219 in focal onset seizures.
- RAP-219 is also being evaluated for bipolar mania, with data expected in 2027.
- The estimated market opportunity for RAP-219 in focal onset seizures in the United States is $10 billion-$15 billion.
- Rapport is developing a long-acting injectable (LAI) formulation of RAP-219, with Phase 1 PK data anticipated in 2027.
Nov 17, 2025, 1:00 PM
Rapport Therapeutics Discusses RAP-219 Phase II Results and Future Milestones
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics' lead program, RAP-219, demonstrated a best-in-class profile in Phase II proof of concept results for focal onset seizures, showing over 70% overall seizure reduction and 24% seizure freedom over an eight-week period with a highly competitive tolerability profile.
- The company estimates the market opportunity for RAP-219 in focal onset seizures to be a multi-billion dollar opportunity, driven by its novel mechanism of action, favorable tolerability, once-daily dosing, long half-life, and lack of drug-drug interactions.
- Rapport is scheduled to meet with the FDA in Q4 2025 for an end-of-Phase II meeting and plans to initiate registrational studies (Phase III) in 2026 for focal onset seizures.
- Additional milestones include data for RAP-219 in bipolar mania expected in 2027 and Phase I PK data for a long-acting injectable formulation also in 2027.
Nov 17, 2025, 1:00 PM
Rapport Therapeutics Reports Positive Phase 2 Results for RAP-219 and Outlines Future Development Plans
RAPP
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Rapport Therapeutics' lead program, RAP-219, a TARPγ8 AMPA modulator, has shown a best-in-class profile in focal onset seizures based on recently released Phase 2 proof of concept results.
- The Phase 2 study demonstrated over 70% overall seizure reduction and 24% complete seizure freedom over an eight-week treatment period, with a safe and well-tolerated profile.
- The company is scheduled to meet with the FDA in Q4 for an end-of-phase-two meeting and plans to initiate pivotal studies in 2026.
- RAP-219 is also being evaluated in bipolar mania, with data from that study anticipated in 2027.
- Rapport is developing a long-acting injectable (LAI) formulation for epilepsy patients, with Phase 1 PK data expected in 2027, which could represent a significant market opportunity.
Nov 17, 2025, 1:00 PM
Rapport Therapeutics Provides Update on RAP-219 Clinical Development and Financial Position
RAPP
New Projects/Investments
Guidance Update
- Rapport Therapeutics' lead program, RAP-219, a TARP gamma-8 AMPA modulator, demonstrated robust efficacy in a proof-of-concept study for epilepsy, showing a 78% median reduction in clinical seizure frequency and a 24% seizure freedom rate. The tolerability profile was encouraging, with a 10% discontinuation rate.
- The company is on track to meet with the FDA by the end of 2025 for an end-of-phase two meeting and expects to initiate two parallel registrational (Phase 3) studies for focal epilepsy by Q3 2026.
- Beyond epilepsy, RAP-219 is also in development for bipolar mania, with data anticipated in 2027, and a long-acting injectable formulation, with human PK data also expected in 2027.
- Rapport Therapeutics ended Q3 with over $500 million in cash, providing a cash runway through 2029 to fund pivotal studies, the bipolar study, the long-acting injectable program, and discovery efforts.
Nov 13, 2025, 6:20 PM
Rapport Therapeutics Reports Q3 2025 Financials and Positive RAP-219 Phase 2a Results
RAPP
Earnings
New Projects/Investments
- Rapport Therapeutics reported a net loss of $26.9 million for the third quarter of 2025, compared to $17.5 million in the prior year period, with Research and Development (R&D) expense increasing to $22.3 million.
- The company ended the third quarter of 2025 with $513.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029.
- Positive topline results were announced from the Phase 2a clinical trial of RAP-219 in focal onset seizures, demonstrating a 77.8% median reduction in clinical seizures and 24% of patients achieving seizure freedom.
- Following a public offering that generated approximately $269.4 million in net proceeds, the company plans to initiate two Phase 3 pivotal trials for RAP-219 in focal onset seizures in the third quarter of 2026.
Nov 6, 2025, 12:15 PM
Rapport Therapeutics Reports Strong Phase 2 Data for RAP-219 and Outlines Future Plans
RAPP
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Rapport Therapeutics announced impressive Phase 2 data for RAP-219 in treatment-resistant focal epilepsy, demonstrating a 78% median reduction in clinical seizures and a 24% seizure freedom rate.
- The trial showcased a differentiated tolerability profile with a 10% discontinuation rate, which is considered very low for proof-of-concept studies in this patient population, and no observed aggression or rage.
- Management believes RAP-219 has a multi-billion dollar market opportunity, potentially exceeding initial peak sales estimates of $1.5 billion due to its profile and anticipated broad adoption by general neurologists and internists.
- The company is funded into the second half of 2029, enabling the initiation of two parallel Phase 3 studies in Q3 2026 for focal onset seizures, as well as advancing a long-acting injectable and a bipolar mania trial.
Sep 17, 2025, 3:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more